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ABSTRACT 
The fundamental approach for the microsponge technologies arises in solid dosage forms because they showing a promising technology for 
nifedipine drug in hypertension control. As nifedipine drug is chosen due to its hydrophobic nature second short half-life, third low remark in 
plasma concentration. Cyclodextrin-based microsponges with different polymer are novel finding in the microsphere technology, the 
crosslinking of polymers blends with respect to cyclodextrin will enhance the entrapment of nifedipine drug in the new-fangled form by 
emulsification solvent method and futher Lyophilization. The different microsponges batches are formulated the optimize batch was MN3 with 
angle of repose; 21.80 ± 0.63., Hausner ratio 1.132, Carrs  index 0.132 and higher % drug content (80.5 ± 0.97 %). showed 99.41 ± 1.05 % drug 
release during 36 hr in vitro release . After that the stability data disclose superior drug retention of loaded nifedipine, besides consistent in vitro 
release pattern over a period of 90 days.  
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1. INTRODUCTION 
Cross-linking of the polymer sphere are dressed up in new-
fangled form of delivery known as microsponges. They are 
spherical, uniform polymer particle having a capacity to 
absorb or to load high degree of active constituents in their 
body or surface due to a larger size and surface area as 
compared to nano bioactive substance (nanospheres and 
nanoshells). The entrapment of drug in microsponge is high 
as compared to other controlled dosage forms that’s why we 
prefer such formulation. Microsponges are a sanctified 
therapeutic system for a transdermal system but recently it 
also shows second-hand practice in oral drug delivery 
system. A calcium channel blocker Nifedipine is used in the 
treatment of angina pectoris and hypertension. The 
complications of hypertension are said to be end-organ 
damage because damage to these organs is the end result of 
chronic high blood pressure. That’s why the diagnosis of high 
blood pressure is important so efforts made to prevent 
complications and normalize blood pressure. It was 
previously thought that rise in diastolic blood pressure was a 
more important risk factor than systolic elevations, but it is 
now known that in people 50 years or older systolic 
hypertension represents a greater risk. If we give the 
impression on patient compliance a once- or twice-daily 
administration of the antihypertensive agent is known to 
increased in dosing scheme if we develop controlled or 
sustainable system for poor half-life drug the frequency of 
drug will be reduced so the side-effects reduce parallel 
which is the need of study. Furthermore, although a blood 
pressure reduction lasting for 24 hrs has never been proven 
to be a precondition for the avoidance of cardiovascular 
complications; it is over and over again browbeaten as an 
argument to support antihypertensive drugs1. For together 
reasons, the pharmaceutical industry is intensively probing 
for longer-acting antihypertensive drugs, either by the 
development of novel agents with a longer eradication of 
half-life problem, or by the upgrading of the galenic form of 
existing shorter-acting compounds, accordingly that plasma 
concentrations well-matched with a blood-pressure-
lowering activity are maintained during the whole phase of 
the day. Many figures of antihypertensive drugs have been 
permitted by the regulatory bodies for once-daily 
administration2,3. On the other hand, no uniform set of 
scientific substantiation present that would be uniformly 
required to obtain approval for a once-daily dosing scheme.  
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Nifedipine microsponges get surplus advantage when we 
incorporate β-cyclodextrin, in them the member of cyclic 
oligosaccharides composed of α-(1, 4) linked glucopyranose 
subunits  give us promising tools for the sustainability and it 
act as molecular hosts toward various, poorly water-soluble 
drugs, ranging from ion, very polar molecules to non-polar 
molecules, affecting advantageously their physicochemical 
properties4. 
The target of the research work is to achieve the desired in-
vitro sustainable release activity of prepared nifedipine 
loaded β-cyclodextrin microsponges with different polymer 
ratio the study is focused on the exploring the microsponges 
technology5-8 to load nifedipine inside them and found the 
release rate through the prepared system. Another reason 
why nifedipine has been chosen is its hydrophobic nature, 
From the literature studies, it is found that it has a short half-
life too and if a drug is used in oral dosage form need for 
higher stability in the stomach9-13. The drug leading low 
remark in plasma concentration curve when trace by 
conventional capsule form of nifedipine. In case of increasing 
its therapeutic efficacy of drug several dosage forms with 
novel approaches are available in literature alginate gel 
beads, chitosan microparticles, poly [DL-lactide-co-glycolide] 
[PLGA] microsphere, Eudragit microparticles and albumin 
microspheres14-19.  
2. MATERIAL AND METHOD 
Nifedipine drug was obtained as a gift sample from Lupin 
Ltd. Mandideep, Bhopal (MP) India. β-cyclodextrin, 
Ethylcellulose, acetone, sodium lauryl sulfate, Tween was 
purchased from Sigma Aldrich, USA. Polyvinyl alcohol, poly 
(D, L-lactic-co-glycolic acid)PLGA, starch, talc and 
Magnesium stearate, Dichloromethane was purchased from 
S.D. Fine chemicals, Indore (MP), India. All the ingredients 
were of analytical grade. 
2.1.  Formulation of Microsponges 
The microsphere was prepared by emulsification-solvent 
evaporation method by preparing multiple emulsion water 
in oil in water (w/o/w).  The inner aqueous phase was 
composed of Nifedipine β -CD complex solution (β-CD show 
increasing the aqueous solubility of Nifedipine so β-CD was 
chosen). The organic phase was composed of varying 
amounts of PLGA in 30 ml of dichloromethane(DCM). The 
inner aqueous phase was emulsified in organic phase 
forming the primary emulsion (w/o), using homogenizer 
(Polytron® PT 10/35 GT) at 21000 rpm for 5 min. Three 
different polymer ratios were used (1:5, 1:10 and 1:20) with 
a drug. The w/o/w multiple emulsion was acquired by 
addition the primary emulsion in 100 ml of PVA(1%). The 
resultant mutiple emulsion was continuously blended to 
allow solvent evaporation. The solid microspheres obtained 
were isolated by centrifuge (Jouan, KR22i, France) at 15000 
rpm for 15 min, washed several times with distilled water, 
and finally, lyophilized. The whole procedure was repeated 
in triplicates. 
2.2 Incoporation of Microsponges in Tablet Formulation 
The directly compressible tablet was prepared by using 
prepared microsponges of nifedipine. The tablets were 
prepared with the use of two mainly used directly 
compressible ingredient, starch and microcrystalline 
cellulose (Avicel PH 101).  Tablets were prepared from 
microsponge formulation MN-3.  Batches prepared were 
denoted as TMN3-1, TMN3-2, TMN3-3 based on the results 
obtained using drug content determination. Tablets of 
weight 30 mg equivalent microsponges were compressed by 
direct mixing of ingredients on the multistation compression 
machine (Secor, India). 
2.3. Experimental Work 
2.3.1. TLC Retention factor (Rf) determination for drug 
excipient interaction: 
Rf value of the nifedipine at room temperature and elevated 
temperature 50˚C was determined using established thin 
layer chromatographic (TLC) method as described away [17] 
and found to be between the range 0.67-0.69. If Rf value 
found in this range indicates that there was no interaction 
between the nifedipine and excipients and we can be 
selected for the further use.  
2.3.2. Drug Content 
30 mg of microsponge was dissolved in 30 ml of chloroform, 
filtered through Whatman filter paper, then 0.2 ml filtrate 
was diluted to 10 ml Chloroform and analyzed 
spectrometrically using at 244.5 nm. Further, the drug 
content was determined by using calibration curve prepared 
in chloroform. The study was done in triplicate. The drug 
content (Production Yield PY) was determined using the 
formulae:  
Practical mass [microsponges] 
PY [%] = ------------------------------------------------- × 100 
Theoretical mass [polymer + drug] 
2.3.3. Morphology of nifedipine microsponges  
The shape and surface characteristics of microspheres were 
examined by an optical microscope (Labtech, India) and 
scanning electron microscopy (SEM) (LEO, 1450 VP, 
England), respectively. Samples were prepared on stubs and 
coated by Gold. Zeta potential was determined by using 
Zetasizer (3000HSA, Malvern, UK) after suitable dilution 
with double distilled water. Results were reported as 
Means±SD.  
2.3.4. Flow Property of nifedipine microsponges 
The microsponges are evaluated for tapped density bulk 
density by measurement of graduated cylinder and angle of 
repose by funnel method.  
2.3.5. Evaluation of tablet incorporated nifedipine 
microsponges 
Weight variation test was performed on 20 tablets of each 
tablet batch TMN3-1, TMN3-2, TMN3-3. The hardness of 
prepared tablets was calculated by Monsanto hardness 
tester. The experiment was performed in triplicate. Drug 
content was determined on average 5 tablets by dissolving 
the whole tablet in chloroform and by its filtration. The final 
amount was determined by plotting a calibration curve of 
nifedipine in chloroform. This is the main In-vitro evaluation 
parameter for testing the sustained release activity of the 
tablets prepared. In vitro dissolution of prepared 
microsponges, tablets were carried out by USP XXXIII 
apparatus paddle type by using distilled water with 0.5% 
w/v Sodium Lauryl Sulphate (SLS) as dissolution media. 
3. RESULTS AND DISCUSSION 
3.1 Results  
The nifedipine sustainability is the basic need to prepare 
microsponges, the technology in the sustainable 
pharmaceutical dosage form. Therefore we have tried to 
formulate sustained releases microsponges tablets of 
nifedipine for effective clinical applications. Preparations of 
microsponges were carried out at different percentage of 
drug and polymer. These batches are designated as MN-1, 
MN-2, and MN-3. (Table 1). The drug excipient interaction 
studies was carried by  the Rf value of the nifedipine at room 
temperature and elevated temperature 50˚C was found to be 
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between the range 0.67-0.69. Nifedipine and β-CD are found 
to be 0.068±0.002 and α-CD shows 0.065±0.031 Rf value 
This indicates that there was no interaction between the 
nifedipine and CD but the Rf value of β-CD shows better 
result that’s why preferred over α-CD. The electron 
microscopy firgure revealed the sponges like  structure of 
the prepared nifedipine microsponges. The image (Fig 1) 
clearly reflecting the surface properties of prepared 
microsponges The batch is accelearated at the voltage of 
10KV and magnification scale at 2000X and 8000X the 
average size range was found to be 0.93µm. Drug content 
was tested in 30 mg each of microsponges from each batch. It 
was found that MN-3 batch was highest dug content whereas 
MN-1 was found to lowest the variation lies between the 
97.68% to 99.41% (Table 1).  
Further the tablet was punched successfully white in color, 
round flat surfaces.The weight variation test was performed 
on 20 tablets of each tablet batch. The prepared 
microsponges tablet batches were found to be within limits. 
All the batches act in accordance with the weight variation 
test as per I.P. data is shown in Table 2. The hardness of 
prepared tablets was calculated by Monsanto hardness 
tester, average hardness was found to be under 5kg/cm2 and 
found to be of good quality, the obtained result is mentioned 
in Table 2. 
 Drug content was determined on average 5 tablets by 
dissolving the whole tablet in chloroform and by its filtration 
amount was determined by calibration curve of the drug in 
chloroform. (Table 2). As the important In-vitro evaluation 
parameter for testing the controlled release activity of the 
tablets prepared the dissolution of prepared microsponges 
tablets were carried out by using USP XXXIII apparatus 
paddle type by using distilled water with 0.5% w/v Sodium 
Lauryl Sulphate (SLS) as dissolution media. The formulation 
TMN-3 was found to be the better formulation with just 
89.55±0.76 % drug release in 24 h. (Table 3; Fig 2). 
 
Table 1: Representing nifidipine polymer ratio, Bulk density, Tapped density, angle of repose, production yield and drug content 
of different formulations with deviation in polymer ratio(Results are expressed as mean values±SD (n=3) 
S. No Formulation 
Code 
CD:Drug: 
Polymer 
ratio 
Carr’s 
Index 
Hausner 
Ratio 
Angle of Repose 
(Type  of Flow) 
(% w/w) 
Production 
yield 
(% w/w) 
% Drug 
content 
Zeta 
potential 
1 MN-1 1:1:5 0.1135 1.1135 (36.32 ±0.96) 
Poor flow 
50.21% 39% -23.3 
2 MN-2 1:1:10 0.1454 1.1454 (25.30±1.09) 
Free flowing 
63.23% 63% -34.3 
3 MN-3 1:1:20 0.1325 1.1325 (21.80±0.63) 
Free flowing 
72.31% 
 
80.5% -34.2 
 
Table 2: The table containing different evaluation parameters for microsponge tablets after direct compression Hardness, Avg. 
weight and % drug content of different formulations TMN3-I, TMN3-II, TMN3-III. (Results are expressed as mean values±SD 
(n=3) 
Sr. 
No 
Formulation 
code 
Avg. Hardness 
kg/cm2 
Average Weight 
(mg) 
Average Drug content per 
tablet in mg 
% Drug 
content 
1 TMN3-I 4.3±0.31 100±0.34 29.3042 97.68±1.02 
2 TMN3-II 4.3±1.07 101±0.89 29.3361 98.45±0.62 
3 TMN3-III 4.4±0.16 100±0.96 29.6241 99.41±1.05 
 
 
Table 3: In vitro dissolution study of directly compressible nifedipine microsponges tablets. (Results are expressed as mean 
values±SD (n=3) 
FORMULATION  TMN-I TMN-II TMN-III 
S.No. Time (hours) % Cumulative Release 
1 0 0 0 0 
2 2 8.37±0.16 8.47±1.33 10.54±0.36 
3 4 15.55±0.86 17.36±1.41 13.21±0.98 
4 6 53.14±1.25 29.32±0.89 20.96±0.91 
5 8 55.98±0.96 42.11±0.84 37.31±0.45 
6 10 87.12±0.11 60.86±0.75 65.44±0.57 
7 12 92.26±0.34 84.54±0.37 75.86±0.69 
8 16 98.32±0.75 88.6±0.66 78.44±0.46 
9 24 98.36±0.68 98.14±0.36 79.35±0.73 
10 30  98.11±0.47 85.49±0.16 
11 36   89.55±0.76 
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Figure 1:The SEM prediction of MN-3 Batch is shown at different magnification scale first image shows at 2000X and second 
image is at 8000X focusing on the single microsponges the surface is rigid and containing uneven surface with the different 
porous shell . SEM image was captured at an acceleration voltage of 10 KV. 
 
 
Figure 2: The graph is showing cumulative % drug release from different batches of Microsponges containing CD and PLGA 
which is formulated in tablet form. Nifidipine drug release from tablet was quantitatively measured by decisive the absorbance 
in UV-visible spectrophotometer at 244.5 nm. Results are articulated as mean values±SD (n=3) 
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3.2 Discussion 
The selection of  materials fis critical process in formulation, 
being researcher it is very important to choose the excipient 
as per the experimental condition, the better outcomes 
always replace the second choice same condition occur with  
α and β-CD. As we know in between α and β-CD, α-CD was 
more effective than a β-CD but when we incorporate both 
materials with nifedipine α-CD shows 0.065±0.031 Rf value 
and β-CD exhbits 0.068±0.002 retention factor, so we 
incorporate β-Cyclo dextrin in our preparation instead of 
another one.  
Morphologically sponges are prepared with porous in nature 
in SEM results it reveals the dimension of microsponges 
ranged in 1.00 µm to 4.00 µm, as the microsponges were 
prepared by lyophilization technique no crystallization of 
drug is seen on the surface of sponges all the drugs was 
entrapped inside the porous space provided on 
microsponges. The structural formulation is found to be a 
spherical shape which is shown in figure 2 (b) at a zoom of 
8000X the porosity of the sphere showing that the drug is 
entrapped inside the small pores, the inert matrices of 
spherical shape with the higher concentration of polymer 
firmly load nifedipine inside them.  
The PLGA that we used in the formulation has the 
uniqueness with amphiphile polymer and capsule of self-
assembling into the polymeric microsponges formulation 
which shows high binding with nifedipine results in the high 
entrapment efficiency. The inert matrices prepared will be 
fabricated so we can see stiffness and resourcefulness in the 
wide range of feat which is a benchmark in pharmaceutical 
companies in casting, molding, extrusion, for catching with 
any sense of biocompatible product formulations.  
In probationary microsponges production initially, we tried 
for series of an organic solvent which includes ethanol, 
methanol, acetone, dichloromethane. The resultant higher 
solubility of PLGA is found in dichloromethane, so we prefer 
it. Manufacturing of microsponges was done by solvent will 
give better results compared to another solvent.  
The selection of polymer ratio is for the increase in 
production yield, the PLGA polymer is biodegradable in 
nature so there is no harm to use this polymer inside body 
by oral route they undergo there hydrolysis of their ester 
linkage in presence of water to produce their monomers, 
lactic acid, glycolic acid which are byproducts of various 
metabolite activity, second advantage is retention effect 
which is shown in figure 2 in sense of drug release. The 
compressibility of microsponges did not give hardness and 
friability for direct compression so to convert into tablet 
form we will add direct compression (Avicel 101PH) so to 
convert into tablet form we will add directly compressible 
material in it to attain a good tensile strength.  
Now on the matter with of drug release, the biggest question 
will arise in how much time or of how much time we have to 
control blood pressure, because as a person during a course 
of a day do different activities to alter their blood pressure. 
This could be not answered by a physician also how much 
pressure should be reduced by the mean of medication with 
effective time, therefore, hypertension disease gives a wide 
area of research and still projects going on. As demonstrated 
in the graph three different polymer ratio is given with 
release rate. The polymer ratio is given with release rate, the 
release rate of batch TMN3-I shows curve lag followed by 
sudden burst effect may be due to less concentration of the 
polymer the achievement which is our target may not be 
achieved. TMN3-II and TMN3-III ideally follow zero order 
(linear release) but the time period for both the drug is 
different this I was shown by two reasons: first, the retention 
time of PLGA is increased by the increase in the polymer 
ratio. Second, the releasing rate of increasing or retarding 
effect of CD, incorporation of a higher amount of CD into the 
microsponges improves the hydration of microsponges. The 
addition of CD in this research shows that it enhances the 
nifedipine release by acting as channeling or wicking agents 
or by promoting erosion of the matrix. In the phase between 
60 to 90hrs the constant effect may be seen because when 
microsponges reaches in the aqueous medium water 
penetrate towards the centre of dimension then the diffusion 
in the porous network is highly limited due to cramped space 
and get slow until pores grow in size then only they will be 
able to release drug by polymer erosion. 
4.  CONCLUSION 
Microsponges set their own standards in the solid dosage 
form drug delivery in relative dosage form they show there 
touchstones in floating drug delivery, effervescent 
technology, sustain release, control release, fluctuation 
release system, osmotic regulation etc through such system 
incalculably primitive dosage form get advantage 
appearance, facilitates accurate delivery of small quantities 
of potent drugs, improve drug integrity, protection of API, 
taste masking, sustain release, reduce gastric irritation, 
separation of incompatibility, reduction of volatility 
(vitamins), stabilization. 
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